Catalyst Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $40.4K | Sell |
320
-101
| -24% | -$13.3K | ﹤0.01% | 306 |
|
|
2026
Q1 | $58.7K | Sell |
421
-60
| -12% | -$8.4K | ﹤0.01% | 286 |
|
|
2025
Q4 | $59K | Sell |
481
-136
| -22% | -$16.5K | ﹤0.01% | 316 |
|
|
2025
Q3 | $68.5K | Sell |
617
-147
| -19% | -$16.7K | ﹤0.01% | 376 |
|
|
2025
Q2 | $84.7K | Sell |
764
-196
| -20% | -$20.9K | ﹤0.01% | 356 |
|
|
2025
Q1 | $108K | Sell |
960
-2
| -0.2% | -$206 | ﹤0.01% | 298 |
|
|
2024
Q4 | $88.9K | Hold |
962
| – | – | ﹤0.01% | 317 |
|
|
2024
Q3 | $80.7K | Sell |
962
-252
| -21% | -$19.2K | ﹤0.01% | 293 |
|
|
2024
Q2 | $83.3K | Buy |
1,214
+40
| +3% | +$2.67K | ﹤0.01% | 234 |
|
|
2024
Q1 | $86K | Buy |
1,174
+4
| +0.3% | +$308 | ﹤0.01% | 221 |
|
|
2023
Q4 | $94.8K | Buy |
1,170
+247
| +27% | +$19.2K | ﹤0.01% | 204 |
|
|
2023
Q3 | $69.2K | Buy |
923
+235
| +34% | +$18.1K | ﹤0.01% | 239 |
|
|
2023
Q2 | $53K | Sell |
688
-35
| -5% | -$2.79K | ﹤0.01% | 268 |
|
|
2023
Q1 | $60K | Sell |
723
-256
| -26% | -$21.2K | ﹤0.01% | 249 |
|
|
2022
Q4 | $84K | Sell |
979
-21
| -2% | -$1.66K | ﹤0.01% | 220 |
|
|
2022
Q3 | $62K | Sell |
1,000
-1
| -0.1% | -$63 | ﹤0.01% | 244 |
|
|
2022
Q2 | $62K | Sell |
1,001
-2,514
| -72% | -$156K | ﹤0.01% | 263 |
|
|
2022
Q1 | $209K | Sell |
3,515
-404
| -10% | -$25.8K | 0.01% | 238 |
|
|
2021
Q4 | $284K | Sell |
3,919
-59
| -1% | -$4.06K | 0.01% | 201 |
|
|
2021
Q3 | $278K | Sell |
3,978
-18
| -0.5% | -$1.26K | 0.01% | 214 |
|
|
2021
Q2 | $275K | Buy |
3,996
+3,252
| +437% | +$217K | 0.01% | 223 |
|
|
2021
Q1 | $48K | Sell |
744
-139
| -16% | -$8.96K | ﹤0.01% | 277 |
|
|
2020
Q4 | $51K | Sell |
883
-2,117
| -71% | -$128K | ﹤0.01% | 274 |
|
|
2020
Q3 | $190K | Sell |
3,000
-1,500
| -33% | -$104K | 0.01% | 237 |
|
|
2020
Q2 | $346K | Sell |
4,500
-9,400
| -68% | -$720K | 0.02% | 202 |
|
|
2020
Q1 | $1.04M | Buy |
+13,900
| New | +$960K | 0.05% | 124 |
|
|
2018
Q2 | – | Sell |
-50,514
| Closed | -$3.81M | – | 514 |
|
|
2018
Q1 | $3.81M | Buy |
50,514
+3,165
| +7% | +$252K | 0.14% | 90 |
|
|
2017
Q4 | $3.39M | Sell |
47,349
-1,305
| -3% | -$99.1K | 0.13% | 94 |
|
|
2017
Q3 | $3.94M | Sell |
48,654
-8,055
| -14% | -$616K | 0.17% | 89 |
|
|
2017
Q2 | $4.01M | Buy |
56,709
+3,437
| +6% | +$229K | 0.17% | 92 |
|
|
2017
Q1 | $3.62M | Buy |
53,272
+5,103
| +11% | +$359K | 0.18% | 101 |
|
|
2016
Q4 | $3.45M | Buy |
48,169
+1,280
| +3% | +$95.1K | 0.22% | 87 |
|
|
2016
Q3 | $3.71M | Sell |
46,889
-177
| -0.4% | -$14.4K | 0.41% | 59 |
|
|
2016
Q2 | $3.93M | Sell |
47,066
-95,503
| -67% | -$8.48M | 0.73% | 51 |
|
|
2016
Q1 | $13.1M | Sell |
142,569
-6,900
| -5% | -$622K | 2.2% | 3 |
|
|
2015
Q4 | $15.1M | Buy |
149,469
+26,065
| +21% | +$2.71M | 2.19% | 3 |
|
|
2015
Q3 | $12.1M | Buy |
123,404
+91,323
| +285% | +$10.1M | 1.63% | 10 |
|
|
2015
Q2 | $3.76M | Sell |
32,081
-45,789
| -59% | -$5M | 0.44% | 85 |
|
|
2015
Q1 | $7.64M | Buy |
77,870
+74,930
| +2,549% | +$7.61M | 0.88% | 31 |
|
|
2014
Q4 | $277K | Buy |
2,940
+738
| +34% | +$76.3K | 0.03% | 288 |
|
|
2014
Q3 | $234K | Buy |
+2,202
| New | +$216K | 0.03% | 275 |
|
|
2013
Q3 | – | Sell |
-1,976
| Closed | -$101K | – | 291 |
|
|
2013
Q2 | $101K | Buy |
+1,976
| New | +$103K | 0.08% | 224 |
|
Other funds holding GILD
Catalyst Capital Advisors's GILD Position: Q2 2026 in Review
Catalyst Capital Advisors reduced its Gilead Sciences (GILD) stake by 24% in Q2 2026, selling an estimated $13.3K and leaving 320 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #306.
Catalyst Capital Advisors first reported a position in GILD in Q2 2013 and has held it in 42 quarters since. The position peaked at $15.1M in Q4 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Catalyst Capital Advisors held 320 shares of Gilead Sciences worth $40.4K as of Q2 2026.
- Catalyst Capital Advisors sold 101 Gilead Sciences shares in Q2 2026, an estimated $13.3K.
- Gilead Sciences made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #306 holding.
- Catalyst Capital Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 42 quarters since.
- Catalyst Capital Advisors's Gilead Sciences position peaked at $15.1M in Q4 2015.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.